La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Helix BioPharma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Helix BioPharma..

Helix BioPharma (OTC:HBPCF) Azioni, Catena delle Opzioni

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.

HELIX BIOPHARMA CORP by Helix Biopharma Corp.

Helix BioPharma Corp

News

OTLK

Outlook Therapeutics Announces Preliminary Topline Results Of Norse Eight Clinical Trial - The Second Of Two Clinical Trials Evaluating ONS-5010 In Wet AMD Patients; Plans To Resubmit The Biologics License Application Application For ONS-5010 In Q1 2025

Shares of&nbsp;Super Micro Computer Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) are showing signs of recovery after a significant drop earlier this week. The stock saw a 2.14% increase in pre-market trading on Wednesday, following a<a href="https://www.benzinga.com/24/11/42207128/smci-drops-10-after-repaying-bank-loans-and-terminating-agreements"> steep 10.4% decline</a> on Tuesday.
What Happened:&nbsp;SMCI announced the termination of two major loan agreements, which led to the initial drop in stock value.&nbsp;The company disclosed in an SEC filing&nbsp;that it had prepaid and&nbsp;ended its loan agreements with&nbsp;Cathay Bank&nbsp;and&nbsp;Bank of America N.A.&nbsp;on Nov. 20. This move is part of the company&#8217;s strategy to tackle ongoing challenges related to&nbsp;Nasdaq listing requirements and delayed&nbsp;financial reporting.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/24/11/42152947/satellite-images-reveal-north-korea-reportedly-receiving-illicit-oil-from-russia?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Satellite Images Reveal North Korea Reportedly Receiving Illicit Oil from Russia</a>
The company&#8217;s market capitalization is currently $17.39 billion. According to&nbsp;<a href="https://pro.benzinga.com/">Benzinga Pro</a>, the consensus price target from 17 analysts is $531.47, with a high of $1300 from Rosenblatt on Aug. 7 and a low of $23 from&nbsp;JP Morgan on Nov. 6.
The company, known for its AI systems that power Nvidia Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) chips, has been on a rollercoaster ride. Despite these recent challenges, SMCI has experienced a notable rally, with shares <a href="https://www.benzinga.com/trading-ideas/movers/24/11/42166890/smci-surges-65-in-a-week-but-is-volatility-the-new-normal">surging 65% in a week</a>. The stock price rose from $20.03 on Nov. 18 to $33.15 on Nov. 22, as it attempted to recover from a six-month decline that had erased nearly 60% of its value.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42159139/microstrategy-shares-rise-in-monday-pre-market-as-michael-saylor-reveals-mstr-generating-500m-daily-amid-bitcoins-surge?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">MicroStrategy Shares Rise In Monday Pre-Market As Michael Saylor Reveals MSTR Generating $500M Daily Amid&nbsp;Bitcoin&#8217;s Surge (UPDATED)</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Equities

Pre-Market Outlook

Markets

General

NVDA

SMCI

Super Micro Computer Makes Slight Recovery During Wednesday Pre-Market After After Ending Loan Agreements With Major Banks

JP Morgan analyst Anthony Paolone downgrades Alexandria Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>) from Overweight to Neutral and lowers the price target from $133 to $121.

Downgrades

Price Target

Analyst Ratings

JP Morgan Downgrades Alexandria Real Estate to Neutral, Lowers Price Target to $121

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Sana Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) with a Buy and maintains $8 price target.

Reiteration

SANA

HC Wainwright & Co. Reiterates Buy on Sana Biotechnology, Maintains $8 Price Target

The expected quarterly operating expenses savings due to the closure are approximately $7.5 million with the full run rate expected to be achieved by the second half of 2025.&nbsp;
The Company intends to sell the assets related to the storage division activities including its manufacturing facilities for battery cells and packs. This does not impact the solar business sale of batteries for residential and C&amp;I markets.

SEDG

SolarEdge Plans To Cease All Activities Of Its Energy Storage Division, Resulting In Workforce Reduction Of Approximately 500 Employees, Most Of Whom In South Korea - Filing

U.S. stock futures declined in premarket hours as traders digested new appointments for the key cabinet positions by President-elect Donald Trump. Hoards of data are expected to be released today which could give a clearer picture of where interest rates are headed.
Futures for the three major U.S. indices dropped and U.S. Dollar Index fell near the 106.5 level. However, the broader small-cap index Russell 200 futures were trading higher during the premarket. The two-year and 10-year U.S. Treasuries slipped to 4.21% and 4.26% respectively as the expectations of a further 25 basis point rate cut in December rose to just 66.3% now, according to CME Group&#8217;s FedWatch tool.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.34%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.16%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.06%</td>
</tr>
<tr>
<td>R2K</td>
<td>0.59%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Wednesday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was down 0.09% to $600.07 and the Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.27% to $507.96, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Cues From The Last Session
The Dow Jones closed higher by around 124 points to 44,860.31 on Tuesday. The S&amp;P 500 rose 0.57% to 6,021.63, while the Nasdaq Composite rose 0.63% to close at 19,175.58 during Tuesday&#8217;s session. Both, Dow Jones and S&amp;P 500 surged to fresh record levels <a href="https://www.benzinga.com/news/earnings/24/11/42207507/dow-sp-500-settle-at-record-highs-fear-greed-index-remains-in-greed-zone">during the session</a>.
Most sectors on the S&amp;P 500 closed on a positive note, with utilities, communication services, and consumer discretionary stocks recording the biggest gains on Tuesday. However, energy and materials stocks bucked the overall market trend, closing the session lower.
On the economic data front, the S&amp;P CoreLogic Case-Shiller home price index rose 4.6% year-over-year in September versus a 5.2% increase in August. Sales of new single-family homes in the U.S. dipped by 17.3% to an annualized rate of 610,000 in October.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.63%</td>
<td>19,175.58</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.57%</td>
<td>6,021.63</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.28%</td>
<td>44,860.31</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.73%</td>
<td>2,424.31</td>
</tr>
</tbody>
</table>
</figure>
Also read: <a href="https://www.benzinga.com/news/earnings/24/11/42207507/dow-sp-500-settle-at-record-highs-fear-greed-index-remains-in-greed-zone">Dow, S&amp;P 500 Settle At Record Highs, Best Buy Reports Weaker Than Expected Earnings: Fear Index Remains In &#8216;Greed&#8217; Zone</a>
Insights From Analysts Comparing the average performance per day of the S&amp;P 500 Index from 1950 to 2023, Ryan Detrick, CMT and chief market strategist at Carson Group LLC said in an X (formerly Twitter) post that &#8220;now is one of the stronger times of the year for stocks.&#8221;
The chart shared by him showed that the average returns on the index from the dates Nov. 23 to Nov. 30 have been consecutively positive over the last 73 years.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Now is one of the stronger times of the year for stocks. <a href="https://t.co/Hh4kA7xx6V">pic.twitter.com/Hh4kA7xx6V</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1861409159167549682?ref_src=twsrc%5Etfw">November 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Speaking about Tuesday&#8217;s cross-asset volatility, Mark Newton, CMT, Managing Director and global head of technical strategy at Fundstrat Global Advisors LLC said that the markets &#8220;got the long-awaited 10-year Treasury and U.S. Dollar rollover while Crude and Precious metals all fell more than 3% today.&#8221;
He added that &#8220;despite a +0.91% equal-weighted $SPX advance today (Tuesday), some might have felt like the market &#8220;got killed&#8221; Not quite, but important to pay close attention given the Cross-asset Volatility that kicked in today.&#8221;
Upcoming Economic Data
Here are the key events lined up for Wednesday.
<ul>
<li>Initial jobless claims, advanced durable goods orders, U.S. trade balance, retail and wholesale inventories, and the first revision of GDP will be released at 8:30 a.m. ET.</li>
<li>Chicago Business Barometer (PMI) will be released at 9:45 a.m. ET.</li>
<li>Nominal personal income and spending data will be released at 10 a.m. ET.</li>
<li>PCE index and pending home sales data will be released at 10 a.m. ET.</li>
</ul>
Stocks To Watch:
<ul>
<li>Crowdstrike Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) was down over 6% in premarket after it reported a GAAP loss of $16.8 million in the third quarter, compared to the income of $26.7 million in the third quarter of fiscal 2024. Loss from operations as per GAAP standards stood at $55.7 million, compared to income of $3.2 million in the third quarter of fiscal 2024.</li>
<li>Dell Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) declined 13.22% in premarket as the third-quarter revenue came in at $24.37 billion, which missed the consensus estimate of $24.65 billion.</li>
<li>HP Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) dipped 10% in pre-market trading. HP reported in-line earnings for its fourth quarter, while sales topped estimates.</li>
<li>Rigetti Computing, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) jumped over 11% in pre-market trading after dipping 20% on Tuesday. The company announced a registered direct offering of 50 million shares at $2 per unit.</li>
<li>HWH International Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWH#NASDAQ">HWH</a>) was up 100% in premarket after Alset Inc. bought 4,411,764 of its shares for a total of approximately $2.99 million. It was priced at 0.68 each, according to SEC filing.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures rose in the early New York session, advancing 0.25% to hover around $68.96.
The Gold spot rose 1% to 2,673.01 per ounce.
Japanese and Korean markets fell on Tuesday, while Chinese, Australian, Indian and Hong Kong markets ended in green. Most European markets declined.
<ul>
<li>Read next: <a href="http://JD Vance's Investment Playbook Has Bitcoin And ETFs: Here's What Else The VP-Elect Is Betting On">JD Vance&#8217;s Investment Playbook Has Bitcoin And ETFs: Here&#8217;s What Else The VP-Elect Is Betting On</a></li>
</ul>
Image Created Using Midjourney

Economics

CRWD

DELL

RGTI

Major US Stock Futures Slide, Small-Caps Buck Trend: Market Strategist Flags This As The 'Stronger Times Of The Year For Stocks'

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) with a Buy and lowers the price target from $28 to $25.

MDWD

HC Wainwright & Co. Maintains Buy on MediWound, Lowers Price Target to $25

JP Morgan analyst Adrian Heurta upgrades Martin Marietta Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>) from Neutral to Overweight and raises the price target from $515 to $640.

Upgrades

JP Morgan Upgrades Martin Marietta Materials to Overweight, Raises Price Target to $640

Macro Economic Events

Econ #s

France Jobseekers Total For October 2,891.5K Vs. 2,837.9K Prior

Needham analyst John Todaro reiterates Iris Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) with a Hold.

IREN

Needham Reiterates Hold on Iris Energy

The most oversold stocks in the consumer discretionary sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Kohls Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>)</h3>
<ul>
<li>On Nov. 26, Kohl&#8217;s shares are trading lower after the company reported worse-than-expected third-quarter results, cut its FY24 EPS guidance, and projected a net sales decrease of 7%-8%. Tom Kingsbury, Kohl's chief executive officer, said, "Our third quarter results did not meet our expectations as sales remained soft in our apparel and footwear businesses. Although we had a strong collective performance across our key growth areas, including Sephora, home decor, gifting, and impulse, and also benefited from the opening of Babies "R" Us shops in 200 of our stores, these were unable to offset the declines in our core business." The company's stock fell around 20% over the past month and has a <a href="https://www.benzinga.com/quote/KSS">52-week low of $14.22</a>.</li>
<li>RSI Value: 26.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>KSS Price Action: Shares of Kohls fell 17% to close at $15.22 on Tuesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112724&amp;t=be2bearmibe3na1">latest KSS news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27063354/image-287.png" alt="" class="wp-image-667133" style="width:647px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27063354/image-287.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27063354/image-287-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27063354/image-287-768x713.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<h3 class="wp-block-heading">Honda Motor Co Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Nov. 6, Honda Motor reported a decline in the first-half profit and lowered its annual profit forecast. The company reported the first half of FY24 revenue growth of 12.4% year over year 10.798 trillion yen ($69.9 billion), while profits declined 19.7% to 494.6 billion Yen ($3.20 billion). The company's stock fell around 17% over the past month and <a href="https://www.benzinga.com/quote/HMC">has a 52-week low </a>of $25.57.</li>
<li>RSI Value: 25.03</li>
<li>HMC Price Action: Shares of Honda fell 3% to close at $25.87 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112724&amp;t=be2bearmibe3na1">HMC stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="923" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27063503/image-288.png" alt="" class="wp-image-667139" style="width:762px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27063503/image-288.png 923w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27063503/image-288-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27063503/image-288-768x701.png 768w" sizes="(max-width: 923px) 100vw, 923px" /></a></figure>
<h3 class="wp-block-heading">PDD Holdings Inc &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>)</h3>
<ul>
<li>On Nov. 21, PDD Holdings reported worse-than-expected third-quarter financial results. PDD reported fiscal third-quarter 2024 revenue growth of 44% year-on-year to $14.16 billion (68.84 billion Chinese yuan), missing the analyst consensus estimate of $14.47 billion. The company's stock fell around 21% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/PDD">low of $88.01.</a></li>
<li>RSI Value: 29.89</li>
<li>PDD Price Action: Shares of PDD fell 1.4% to close at $99.31 on Tuesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112724&amp;t=be2bearmibe3na1">breakout in PDD shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="898" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27063612/image-289.png" alt="" class="wp-image-667140" style="width:744px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27063612/image-289.png 898w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27063612/image-289-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27063612/image-289-768x719.png 768w" sizes="(max-width: 898px) 100vw, 898px" /></a></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42188912/jim-cramer-linde-is-a-terrific-company-sees-another-stock-up-75-as-not-done">Jim Cramer: Linde Is A &#8216;Terrific&#8217; Company, Sees Another Stock Up 75% As &#8216;Not Done&#8217;</a></li>
</ul>

Long Ideas

Trading Ideas

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Top 3 Consumer Stocks That Are Set To Fly In Q4

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and maintains $180 price target.

AXSM

HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $180 Price Target

Needham analyst Mike Cikos maintains Nutanix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) with a Buy and raises the price target from $80 to $90.

NTNX

Needham Maintains Buy on Nutanix, Raises Price Target to $90

K'alo-Stantec has been selected by the Government of the Northwest Territories (GNWT) Department of Infrastructure to continue completing the environment assessment and secure necessary regulatory authorizations for the proposed Mackenize Valley Highway (MVH). K'alo-Stantec has a long-term relationship with GNWT and has been key in maintaining the continuity of advancing the MVH project.
The project will establish a critical transportation corridor into Canada's Arctic, connecting three communities-Wrigley, Tulita, and Norman Wells-by replacing a 320-kilometre winter road with an all-season road.

Contracts

K'alo-Stantec Selected To Provide Environmental Consulting Services For Mackenzie Valley Highway

Needham analyst Mike Cikos maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Buy and raises the price target from $360 to $420.

Needham Maintains Buy on CrowdStrike Holdings, Raises Price Target to $420

Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) has accelerated progress on its advanced 2-nanometer fab in Kaohsiung. The company held an equipment installation ceremony six months before schedule, reflecting its efforts to meet the global demand for advanced chips.
Kaohsiung Mayor Chen Chi-mai highlighted the milestone during a city council Q&amp;A session, noting the facility&#8217;s potential to boost artificial intelligence (AI) applications and stimulate industrial transformation in the region, Taipei Times <a target="_blank" href="https://www.taipeitimes.com/News/front/archives/2024/11/27/2003827547" rel="noreferrer noopener">reports</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42195174/spotify-introduces-marketing-tools-for-audiobook-authors" rel="noreferrer noopener">Spotify Introduces Marketing Tools For Audiobook Authors</a>
The chipmaker plans to establish four additional fabs in Kaohsiung, complementing its existing 3-nanometer and 5-nanometer facilities. According to Mayor Chen, these developments aim to form one of the most valuable semiconductor clusters globally. Several material, equipment, and parts suppliers have also set up operations in the city, further strengthening the ecosystem.
Taiwan Semiconductor confirmed to the Taipei Times that its 2-nanometer technology is on track for mass production next year, with performance and yield already meeting or exceeding expectations. The chipmaker is constructing a similar production line at its Hsinchu facility.
Chairman and CEO C.C. Wei recently told investors that demand for 2-nanometer technology has exceeded expectations, surpassing even the 3-nanometer capacity.
The chips are slated for smartphones and high-performance computing, with Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) expected to adopt them early.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27041315/newplot-14.png" alt="" class="wp-image-666951" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27041315/newplot-14.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27041315/newplot-14-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
<a target="_blank" href="https://www.benzinga.com/media/24/11/42168509/amd-teams-up-with-taiwan-semi-to-take-on-samsung-in-smartphone-market" rel="noreferrer noopener">Recent reports indicated</a> AMD leveraging Taiwan Semiconductor&#8217;s 3nm process to foray into the smartphone market, eying flagship devices like Samsung&#8217;s models.
Taiwan Semiconductor is also preparing capacity for <a target="_blank" href="https://www.benzinga.com/24/11/42060003/taiwan-semiconductors-us-subsidy-boosts-a16-tech-production-in-arizona" rel="noreferrer noopener">its A16 chips</a>, which are in high demand for AI server applications. Wei emphasized the company&#8217;s commitment to scaling 2-nanometer and A16 production to meet customer needs.
The chipmaker targets <a target="_blank" href="https://www.benzinga.com/24/11/42116366/taiwan-semiconductor-plans-new-factories-annually-boosting-domestic-chip-production" rel="noreferrer noopener">capital expenditures of</a> $34 billion—$38 billion in 2025 to meet demand for advanced semiconductor manufacturing.
Price Action: TSM stock is down 1.06% at $181.89 premarket at the last check on Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42193222/orange-taps-openai-meta-to-create-ai-that-speaks-african-languages" target="_blank" rel="noreferrer noopener">Meta, OpenAI, Orange Join Forces To Build AI Models For African Languages</a></li>
</ul>
Photo by wakamatsu.h via Shutterstock.

Tech

Media

AAPL

Taiwan Semiconductor Ramps Up 2nm Production: Apple And AMD First In Line

GSK's fully liquid Menveo meningococcal vaccine approved by European Commission
●
New fully liquid presentation means reconstitution is not needed before use
●
Formulation supports simplification of vaccination process against invasive meningococcal disease (IMD)

GSK's Fully Liquid Menveo Meningococcal Vaccine Approved By European Commission

Needham analyst David Saxon reiterates Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) with a Hold.

Needham Reiterates Hold on Cooper Companies

Needham analyst Mike Matson reiterates Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Hold.

Needham Reiterates Hold on Boston Scientific

QuantaSing Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) reported quarterly earnings of $0.24 per share which beat the analyst consensus estimate of $0.18 by 33.33 percent. The company reported quarterly sales of $115.48 million which missed the analyst consensus estimate of $135.22 million by 14.60 percent. This is a 3.06 percent decrease over sales of $119.13 million the same period last year.

Comments

Helix BioPharma

Helix BioPharma (HBPCF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO